Mounjaro vs Ozempic: An Honest Comparison

“Mounjaro or Ozempic?” is one of the most-searched GLP-1 questions — and the honest answer depends on what you’re treating, what you can get, and how your body responds. Here’s the plain-English comparison.

First, clear up the names

This trips everyone up. There are only two molecules behind four brand names:

So “Mounjaro vs Ozempic” is really tirzepatide vs semaglutide — the same comparison as Zepbound vs Wegovy, just under the diabetes-approved names. (We cover the weight-loss names in Zepbound vs Wegovy.)

How they differ

Mechanism. Ozempic (semaglutide) activates one gut-hormone receptor: GLP-1. Mounjaro (tirzepatide) activates two: GIP and GLP-1. That dual action is the leading theory for why tirzepatide tends to edge out semaglutide on average.

Results. The head-to-head SURMOUNT-5 trial found tirzepatide produced greater average weight loss than semaglutide — about 20% vs 14% of body weight over 72 weeks. For blood sugar, the SURPASS diabetes trials similarly showed tirzepatide with a modest edge on A1c and weight. Three honest caveats:

1. Averages aren’t destiny. Some people lose far more on semaglutide than the average tirzepatide user, and vice versa. You can’t predict your response in advance.
2. The “runner-up” is still remarkable. Fourteen percent average loss was unimaginable in a medication a few years ago.
3. The best drug is the one you can actually get and tolerate.

Side effects. Both share the same core gastrointestinal profile — nausea, constipation, diarrhea, mostly early and around dose increases — at broadly similar rates. Individual tolerance varies more than the averages do. Our side-effect guide applies to either.

Approval and access

Because Ozempic and Mounjaro are FDA-approved for type 2 diabetes, insurance coverage often hinges on your diagnosis. Many people with diabetes get one of these covered, while weight-management coverage (Wegovy/Zepbound) is spottier. This is why the “which drug” question is frequently answered by your insurance formulary, not pharmacology.

Cost

Both list above $1,000/month without insurance, and both manufacturers run direct-purchase and savings programs well below list. What you actually pay depends far more on your coverage and diagnosis than on which molecule you pick. Walk the full decision in our real-cost map.

How to actually decide

Bring three questions to your prescriber:

1. Which does my insurance cover for my diagnosis?
2. Is there a clinical reason to prefer one for my history?
3. If the first choice plateaus or isn’t tolerated, what’s the switching plan?

That conversation beats any internet comparison — including this one. Both are powerful, well-studied medications; the “winner” is whichever one you can get, afford, and stay on.